retatrutide phase 2 nejm 2023 obesity trial jastreboff Michael Weintraub, MD on X: "Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released results demonstrating 25% weight loss in half of people with #obesity. This amount of weight Retatrutide Phase 3: 28.7% Weight

Management of diabetic retinopathy should follow established clinical guidelines and practice patterns, including anti-VEGF therapy, laser or surgery as indicated

You have to be careful with thatwhen excitement precedes the proof or evidence and risk profile, says Dr

Like, what is the argument against, given that we know how these things work

The hormonal imbalances and insulin resistance that come with PCOS can make Cysters gain weight quickly, especially around the belly

Why Might GLP-1 Medicines Help

You will learn how they function alongside practical recommendations to maximize benefits and minimize side effects